AKT1 and colorectal carcinoma: CRC patients with PIK3CA and KRAS mutations are unlikely to respond to the inhibition of the MEK pathway alone or the PI3K pathway alone but will require effective inhibition of both MEK and PI3K/AKT signaling pathways [12,13,16,34,39,50,51,52,53,54,55].